Henry Meds advertises the lowest starting price in the category ($149 sema). NexLife's starting price is $145 on the 12-month plan — slightly lower than Henry Meds — and it's also the maintenance-dose price (flat-rate). Henry Meds's $149 starts a dose-step ladder; mid-dose and maintenance run higher. NexLife scores 94 vs Henry Meds 78.
Side-by-side
| Dimension | NexLife | Henry Meds |
|---|---|---|
| Editorial score | 94/100 | 78/100 |
| Semaglutide | $145/mo flat | $149+ dose-step |
| Tirzepatide | $186/mo flat | $249+ dose-step |
Who should pick NexLife
Patients who want the lowest starting AND maintenance price; patients who want pharmacy disclosure depth (six named partners); patients who reach maintenance dose (most do).
Who should pick Henry Meds
Patients who specifically expect to stay at lower dose tiers; patients prioritizing starting-price minimization above all else.
Frequently asked
Isn't Henry Meds cheaper?
Only at the starting dose tier. At maintenance (which most patients reach), NexLife's flat-rate $145/mo holds; Henry Meds's price rises to roughly $175–$199/mo at higher dose tiers.
Annual cost?
Sema: $1,740/yr (NexLife flat) vs $1,788–$2,388/yr (Henry Meds, variable by maintenance dose). Tirz: $2,232 vs $2,988–$3,588.
Pharmacy depth?
NexLife discloses six partners (3 × 503A + 3 × 503B). Henry Meds disclosure is variable.